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Abstract
Background: The aim of the study was to explore Fc mutations of a humanised anti-Lewis-Y antibody (IgG1)
hu3S193 as a strategy to improve therapeutic ratios for therapeutic payload delivery.
Methods: Four hu3S193 variants (I253A, H310A, H435A and I253A/H310A) were generated via site-directed
mutagenesis and radiolabelled with diagnostic isotopes iodine-125 or indium-111. Biodistribution studies in
Lewis-Y-positive tumour-bearing mice were used to calculate the dose in tumours and organs for therapeutic
isotopes (iodine-131, yttrium-90 and lutetium-177).
Results: 111In-labelled I253A and H435A showed similar slow kinetics (t1/2β, 63.2 and 62.2 h, respectively) and
a maximum tumour uptake of 33.11 ± 4.05 and 33.69 ± 3.77 percentage injected dose per gramme (%ID/g),
respectively. 111In-labelled I253A/H310A cleared fastest (t1/2β, 9.1 h) with the lowest maximum tumour uptake
(23.72 ± 0.85 %ID/g). The highest increase in tumour-to-blood area under the curve (AUC) ratio was observed
with the metal-labelled mutants (90Y and 177Lu). 177Lu-CHX-A" DTPA-hu3S193 I253A/H310A (6:1) showed the
highest tumour-to-blood AUC ratio compared to wild type (3:1) and other variants and doubling of calculated
dose to tumour based on red marrow dose constraints.
Conclusions: These results suggest that hu3S193 Fc can be engineered with improved therapeutic ratios for
90Y- and 177Lu-based therapy, with the best candidate being hu3S193 I253A/H310A for 177Lu-based therapy.
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Background
The use of monoclonal antibodies (mAbs) to deliver ra-
dioisotopes to tumour sites (radioimmunotherapy (RIT))
has been very successful in the treatment of haemato-
logic tumours as the targeted radiation is able to kill the
highly radiosensitive leukemias and lymphomas. Treat-
ment of solid tumours that are generally more radiore-
sistant has been less successful due to several factors
including long serum persistence, poor tumour penetra-
tion and slow diffusion rates of mAbs [1]. The large mo-
lecular size of mAbs (150 kDa) does not allow renal
excretion. In addition, the Fc fragment of IgG antibodies
interacts with the neonatal Fc receptor (FcRn, Brambell
receptor), preventing it from being degraded in the lyso-
somes [2–6]. The resulting long serum persistence of
large-sized mAbs cause dose-limiting radiotoxicity to
normal tissues, principally red marrow.
The choice of the optimal radionuclide for RIT de-
pends on its intended use. Physical properties such as
path length, emission energy and physical half-life
must correlate with a particular tumour size. 131I
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(Emax, 0.66 MeV), suitable for tumours <1 cm, and
90Y
(Emax, 2.3 MeV), suitable for tumours >1 cm, are both
β-particle-emitting isotopes and have been used in
>95 % of clinical RIT trials [1]. Similar to 131I, 177Lu
(Emax, 0.5 MeV) has been identified as having
favourable characteristics for treatment of tumours
particularly with heterogeneous antigen expression [7].
Whilst 90Y and 177Lu labels are retained intracellularly
after endocytosis, the 131I label is rapidly released from
the cells [8, 9].
Early engineering approaches to reduce the serum
half-life of antibodies and improve therapeutic ratios
were based on reduction in antibody size by deletion of
constant domains [1, 10, 11]. Our laboratory has previ-
ously evaluated smaller forms such as diabody, F(ab′)2
and tetrameric scFv constructs without an Fc fragment.
These constructs showed a rapid elimination phase com-
pared to wild-type IgG1, more rapid tumour targeting
with the maximum tumour uptake observed at an earlier
time point but strongly reduced maximal tumour uptake
[12–14]. Another approach studied in preclinical studies
to improve therapeutic ratio is pretargeted RIT. The
multistep targeting approach allows the antibody to clear
first before administrating the therapeutic radionuclide,
and this approach has shown high increases in thera-
peutic ratio [1, 15].
The FcRn receptor recycles IgG antibodies into the
blood circulation. During the last decade, the Fc-FcRn
binding site has been well characterised, with I253,
H310 in the CH2 domain and H435 in the CH3 domain
identified as the key residues involved in the Fc-FcRn
binding [16–19]. The FcRn-mediated IgG recycling can
be described as a three-step process: (1) passive pinocyt-
osis of IgG into endothelial cells; (2) in the acidic envir-
onment of endosomes (pH <6.5), histidine residues in
the Fc fragment of IgG become protonated and this
allows high-affinity binding of IgG to FcRn; and (3)
unbound IgG will undergo lysosomal degradation whilst
FcRn-bound IgG is released back into the blood circula-
tion [19]. Therefore, more recent engineering ap-
proaches to reduce the serum half-life of antibodies or
Fc-coupled biological compounds used for payload deliv-
ery focus on mutating the specific amino acids in the
CH2 or CH3 domain of the Fc fragment involved in the
binding site of FcRn. Recycling of the variants is re-
duced, due to their diminished interaction with the FcRn
receptor at pH <6.5. Most work has been done with
radiolabelled Fc-containing antibody fragments such as
scFv-Fc [20–23] and a minibody [22]. Only one intact
radiolabelled antibody (chTNT-3) carrying the I253A
mutation has been studied in biodistribution studies and
imaging studies [24].
We recently produced anti-Lewis-Y (Ley) humanised
IgG1 variants carrying specific mutations in the Fc-FcRn
binding region and investigated their binding properties
to murine FcRn (muFcRn) and human FcRn (huFcRn) in
vitro and in vivo [25]. A good correlation was found
with low in vitro binding to FcRn corresponding to fast
blood clearance rates. Differences in blood clearance
rates were observed between the murine and human
FcRn mouse model, showing that one alanine mutation
in the Fc-huFcRn binding site (i.e. I253A, H310A or
H435A) was sufficient to completely abrogate binding to
huFcRn and generate hu3S193 antibodies with clearance
rates as fast as hu3S193 antibody fragments (e.g. (Fab′)2)
without an Fc fragment. In contrast, two alanine muta-
tions in hu3S193 Fc (e.g. I253A/H310A) were necessary
to completely abrogate binding to muFcRn. Single non-
alanine variants of hu3S193 that were able to completely
abrogate muFcRn binding were I253D, I253P, H310D
and H310E [25].
This study explored the impact of amino acid substitu-
tions on conserved residues of hu3S193 that have been
shown to be critical for maintaining serum persistence
of human IgG1 antibodies as a means to improve thera-
peutic ratios for RIT in solid tumours using intact anti-
bodies. Hu3S193 has been shown to have significant
anti-tumour effect in animal models for delivery of ra-
dioisotopes, including 131I, 90Y and 177Lu [26–29]. A
first-in-man phase I trial of hu3S193 in patients with Ley
expressing tumours clearly showed the potential for
delivery of radioisotopes using hu3S193 for selective tar-
geting of solid tumours [31]. The utility of hu3S193 mu-
tants in cancer diagnosis and therapy were evaluated by
pharmacokinetic, biodistribution, dosimetry and immu-
noscintigraphy studies in tumour-bearing mice.
Methods
Construction of hu3S193 mutant antibodies
The construction and production of hu3S193 and
huA33 has been described before [31, 32]. The hu3S193
heavy chain (HC) was ligated into the pEE6.4 mamma-
lian expression vector (Lonza Biologics, Slough, UK) via
a HindIII and EcoRI double digest (pEE6.4/hu3S193
HC). pEE6.4/hu3S193 HC was used as a template for
site-directed mutagenesis (GeneTailor™ Site-Directed
Mutagenesis System (Invitrogen) or QuickChange II XL
Site-Directed Mutagenesis Kit (Stratagene) to introduce
the following substitutions in the CH2 and CH3 do-
mains: I253A, H310A, H435A and I253A/H310A [25].
The hu3S193 kappa light chain was ligated into the
pEE14.4 mammalian expression vector containing the
glutamine synthetase gene (Lonza Biologics) via a Hin-
dIII and EcoRI double digest. For the simultaneous ex-
pression of each mutated hu3S193 antibody, light and
mutated heavy chain genes were cloned into a double-
gene vector (pDGV) using a NotI and PvuI double
digest. Freestyle 293-F cells (1 × 106 cells/mL) were
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transfected with the pDGV constructs according to the
manufacturer’s instructions (Invitrogen). Supernatants
were harvested at 96 h post transfection. Hu3S193 anti-
bodies were purified using HiTrap KappaSelect columns
(GE Healthcare). Purified proteins were analysed by
SDS-PAGE under non-reducing conditions and evalu-
ated by size exclusion chromatography on a Superdex
200 HR 10/30 column (GE Healthcare) using 0.01 mol/L
sodium phosphate and 0.15 mol/L NaCl (pH 7.2) as elu-
tion buffer.
In vitro binding to Lewis-Y and protein A of hu3S193
mutant antibodies
The Lewis-Y binding activity of hu3S193 antibodies
was determined by BIAcore analysis using a synthetic
Lewis-Y tetrasaccharide coupled to BSA (Alberta
Research Council, Edmonton, Alberta, Canada) on a
CM5 chip using a BIAcore 2000 as described (BIAcore
AB, Uppsala, Sweden) [30]. Hu3S193 antibody samples
were diluted in HBS buffer (10 mM HEPES, pH 7.4,
150 mM NaCl, 3.4 mM di-Na-EDTA and 0.005 %
Tween 20). Aliquots (60 μL) were injected over the
sensor chip surface at a flow rate of 30 μL/min. After
the injection phase, dissociation was monitored by
flowing HBS over the chip surface for 300 s. Bound
antibody was eluted, and the chip surface was regener-
ated between samples by injection of 100 mM HCl.
For kinetic analysis, varying concentrations of hu3S193
wild type and mutants were injected (10, 19, 38, 75 and
150 nmol/L). Global analysis using a 1:1 Langmuir
model fit was performed using BIA-evaluation version
4.1.1 software.
Fluorescence-activated cell sorter (FACS) analysis was
done on Lewis-Y-positive A431 skin cancer cells.
Aliquots of 2 × 105 cells were incubated with hu3S193
antibodies (200 nmol/L) in DMEM/F12 medium con-
taining 10 % foetal bovine serum on ice. After washing
the cells with PBS, cells were incubated with a goat
phycoerythrin-conjugated anti-human IgG (Sigma) and
incubated on ice for 30 min. Cells were washed with
phosphate-buffered saline and resuspended in a final
volume of 300 μL. In control samples, primary antibody
was omitted. Flow cytometric analysis was done using a
Guava EasyCyte Plus flow cytometer. Cancer cell popu-
lations were gated based on forward and side scatter
variables. Data analysis was done using WinMDI
(Joseph Trotter).
Radiolabelling of hu3S193 antibodies
Hu3S193 antibodies were radiolabelled with four isotopes:
125I, 131I, 111In and 177Lu. Iodine-125 and lutetium-177 were
obtained from PerkinElmer (PerkinElmer Life and Analyt-
ical Sciences, Waltham, MA), iodine-131 was obtained
from ANSTO (ANSTO, Menai, Australia) and indium-111
was obtained from MDS Nordion (Canada).
Radioiodination was performed using pH-neutralised
isotopes, catalysed by iodogen-coated glass beads as
previously published [12, 33]. After a 10-min incuba-
tion period, the reaction mixture was purified through
a Sephadex G50 desalting column (Sigma-Aldrich,
Sydney, Australia) equilibrated with 0.9 % NaCl con-
taining 0.05 % human serum albumin.
Radiolabelling of the hu3S193 antibody constructs with
indium-111 and lutetium-177 was done by using the
bifunctional metal ion chelate C-functionalized trans-
cyclohexyl diethylenetriaminepentaacetic acid (CHX-A″
DTPA) [34, 35]. A chelate to antibody ratio of 3:1 was
employed, using 0.1 M sodium bicarbonate buffer (pH
8.6) containing 0.9 % NaCl. Incubation was allowed for
16 h at room temperature. Under these conditions, one to
two chelates are expected per antibody molecule. The
radiolabelled mixture was purified through a Sephadex
G50 desalting column equilibrated with 0.9 % NaCl con-
taining 0.05 % human serum albumin.
Radiolabelling was performed on the day of injection
into mice. Prior to injection, the percentage of unbound
radionuclide content was determined by ITLC as previ-
ously described [36]. Determination of the immunoreac-
tivity of radiolabelled hu3S193 antibody constructs was
performed by a single-point binding assay, where 10 ×
106 Ley-positive A431 cells were incubated with 20 ng
of radiolabelled antibody constructs for 45 min at room
temperature with continuous mixing throughout to
keep the cells in suspension. Cells were washed three
times, and pellets were measured in a gamma counter
(Cobra II, Model 5002, Packard Instruments, Canberra,
Australia). Three samples of radiolabelled antibody at
the same concentration as that initially added to the
cells were measured at the same time of the cell pellets,
and immunoreactivity was calculated: (cpm cell pellet/
mean cpm radioactive antibody standards) × 100. Serum
stability was analysed by determination of immunoreac-
tivity on the day of injection, at 48 h, and 7 days after
20 ng of radiolabelled antibody was incubated in hu-
man serum at 37 °C.
Blood clearance studies
Female athymic mice (BALB/c nu/nu; 4–6 weeks;
Animal Resources Centre) were injected in the tail vein
with 0.185 MBq 125I-mutant (2.5–5 μg, 5 μCi) and
0.185 MBq 131I-hu3S193 (2.5–5 μg, 5 μCi) wild type
antibody (n = 5). A separate group of athymic mice were
injected with 0.185 MBq 125I- hu3S193 mutant (2.5–
5 μg, 5 μCi) and 0.185 MBq 111In-hu3S193 (2.5–5 μg,
5 μCi) mutant (n = 5). All animal studies were approved
by the Austin Hospital Animal Ethics Committee and
were conducted in compliance with NHMRC Australian
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code of practice for the care and use of animals for sci-
entific purposes. Blood samples (10–20 μL) were col-
lected from groups of five at 5 min, 1, 2, 4, 8, 24, 48,
72, 120, 168, 240 and 336 h after injection of radio-
active antibodies. Samples were counted in a gamma
counter (Cobra II). Standards prepared from injected
material were counted each time with blood samples
enabling calculations to be corrected for physical decay
of isotope.
Biodistribution studies
Biodistribution studies were done with athymic non-
tumour-bearing mice (BALB/c nu/nu, female, 4–6 weeks)
or mice bearing A431 tumours (111In, 0.657 ± 0.216 g;
131I, 0.515 ± 0.195 g; 177Lu, 0.466 ± 0.086 g). To study the
tumour uptake and biodistribution in normal tissues of
radioiodinated hu3S193 variants, A431 tumour-bearing
BALB/c nu/nu mice were co-injected intravenously with
0.185–0.74 MBq (5–20 μCi) 131I-hu3S193 variants (2–
6 μg protein) and 0.185–0.74 MBq 125I-hu3S193 wild
type (2–6 μg protein). In a second study, 0.185–
0.74 MBq 111In-CHX-A″ DTPA-labelled mutant (2–
6 μg protein) and 0.185-0.74 MBq 125I-labelled hu3S193
wild type (2–6 μg protein) were co-injected. 111In-CHX-
A″ DTPA-labelled wild type and 125I-hu3S193 wild type
were also injected as a control group. 125I-hu3S193 wild
type was used as an internal control in all injected ani-
mals to enable direct comparison between the different
mutants. Typically, groups of four to five mice were
sacrificed at 4, 24, 48, 72, 120, 168, and 240 or 288 h
after injection of radiolabelled antibodies. For evaluation
of 177Lu-labelled antibodies, mice were sacrificed at 48 h
after injection. At the designated time points, groups of
mice (n = 4–5) were humanely sacrificed by over-
inhalation of isoflurane. Mice were bled by cardiac punc-
ture, and tumours and organs (skin, liver, spleen, small
intestine, stomach, kidney, brain, bone (femur), lungs
and heart) were immediately removed and blotted dry.
All samples were weighed and counted in a dual gamma
scintillation counter (Cobra II, Packard Instruments).
Triplicate standards prepared from the injected material
were counted at each time point with tissue and tumour
samples enabling calculations to be corrected for the
physical decay of the isotopes. Results of the radiola-
belled antibody distribution over time were calculated
as the mean percentage injected dose per gramme
(%ID/g ± SD) for each mutant and parental hu3S193
per time point.
Pharmacokinetic analysis and predictive dosimetry
Antibody serum concentrations were expressed as per-
centage injected dose per millilitre (%ID/mL), and the
blood concentrations (μg/mL) were calculated. A two-
compartment IV bolus model with macro-parameters,
no lag time and first order elimination (WinNonlin
Model 8) was fitted to serum data obtained from blood
clearance studies for each animal using unweighted
non-linear, least squares with WinNonLin version 5.2
(Pharsight Corp., Mountain View, CA). Estimates were
determined for the pharmacokinetic parameters: alpha
half-life (t1/2α), beta half-life (t1/2β), area under the
curve extrapolated to infinity (AUC0-∞) and mean resi-
dence time (MRT). Alpha half-lives of mutant hu3S193
were constrained to be smaller or equal to the alpha
half-life of hu3S193 wild type. Significant differences in
these values were examined by comparing the coeffi-
cient of variation (CV %) for the estimated parameters.
To estimate radioimmunotherapeutic applications
for 90Y- or 177Lu-labelled mutants, biodistribution data
obtained with 111In-CHX-A″ DTPA-labelled antibodies
were used to generate time-activity curves for the calcula-
tions of predictive radiation doses for the bone marrow,
liver, kidneys and tumour. Identical biodistribution and bio-
logic clearance of 111In-, 90Y- and 177Lu-labelled antibodies
were assumed. Predictive dosimetric analysis was also done
for 131I-labelled antibodies based on biodistribution data
obtained with 125I-labelled antibodies. As radiation
absorbed doses are proportional to %ID/g, time-activity
curves for the blood, liver, kidneys and tumour were inte-
grated over time to calculate area under the curve (AUC).
Time-activity curves generated from biodistribution data
were corrected for radiodecay. Therefore, the pharmacoki-
netic values calculated from such data refer to pharmaco-
logical values of the antibodies in the absence of
radioisotope. Appropriate physical half-life corrections were
applied to convert %IDpharmacological/g to %IDradioisotope/g,
and the time-activity curves were fit to either a two or three
exponential function from which the AUC is determined
for 90Y, 177Lu and 131I. AUC integration from zero to infin-
ity was done by the sum of a trapezoidal integration of the
measurement range (AUC0–288 h) plus an extrapolated
model fit for the extrapolated range (AUC288 h–∞). To cal-
culate accumulated activity, photon dose and edge effects
were ignored. Dose to red marrow was determined from
blood concentrations using a baseline value of 0.1 [21].
Nano-SPECT and MR imaging
All the SPECT and MR scans were performed on a small
animal nano-SPECT/CT imaging system and a small ani-
mal nano-PET/MR imaging system (Mediso nano-ScanPM,
Mediso Medical Imaging Systems, Budapest, Hungary) in-
dividually. Groups of two mice were injected with
3.7 MBq (270 μg) 177Lu-CHX-A″ DTPA-labelled antibody
(huA33 wild type, hu3S193 wild type or hu3S193 I253A/
H310) and serially imaged at 2 days post injection. Im-
aging procedures involved anaesthesia of mice by isoflur-
ane. Each mouse was scanned in supine position with its
head secured via ear and tooth bars. Respiration was
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monitored by a pressure-sensitive pad adhered to the ab-
domen. The imaging study started with a whole body
T1-weighted MR scan, followed by a 60-min SPECT scan
which was reconstructed into a volumetric image with the
voxel size of 0.3 mm× 0.3 mm× 0.3 mm using the Mediso
Tera-TOMO® Monte Carlo-based algorithm. Subse-
quently, reconstructed SPECT and MR images were trans-
ferred to a research PACS system where the images could
be retrieved for further processing and analysis.
To confirm data obtained from imaging, groups of five
mice bearing A431 tumours were injected with
6.29 MBq (100 μg) 177Lu-CHX-A″ DTPA-labelled anti-
body (huA33 wild type, hu3S193 wild type or hu3S193
I253A/H310) and sacrificed at 48 h post injection. Or-
gans and blood were collected as described before, and
the radiolabelled antibody distribution over time was
calculated as the mean %ID/g ± SD for each antibody
per time point.
Statistical analysis
To compare tumour uptake at different time points for
the mutants versus hu3S193 wild type, two-way ANOVA
with the Bonferroni post test was performed using
GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego California USA www.graphpad.com.
Tumour-to-tissue ratios or tissue uptake at specific time
points were analysed using one-way ANOVA with
Tukey’s multiple comparison post test. When less than
three groups were compared, a non-parametric t test
(one-tailed) was used.
Results
Production of hu3S193 variants with short elimination
half-lives
To investigate whether hu3S193 antibodies with reduced
serum persistence would benefit payload delivery, three
hu3S193 single variants (I253A, H310A, H435A) and
one double variant (I253A/H310A) were generated. All
antibodies were expressed in transiently transfected free-
style 293-F cells. Expression yields of antibodies ranged
from 15 to 40 mg/L in shake flasks containing 60 mL
medium. HiTrap KappaSelect columns were used to
purify antibodies. Quality control using SDS-PAGE and
HPLC on a Superdex 200 column showed highly pure
antibody preparations with >98 % purity. All mutants
maintained effective antigen binding in FACS analysis
and BIAcore (Additional file 1: Table S1).
Radiolabelling of hu3S193 constructs and huA33 control
Antibodies were radiolabelled with iodine-125 and
indium-111, and radiochemical purity of all injected
antibodies was more than 98 %. Immunoreactivity was
determined in the presence of human serum at 37 °C for
up to 6 days of incubation, as measured by percentage
of antibody binding to Lewis-Y-positive A431 cells in a
single-point immunoreactivity assay. Data presented in
Table 1 demonstrates minimal loss in binding of all vari-
ants compared to wild type at day 0 due to labelling
(20–35 %). Loss of immunoreactivity due to incubation
in human serum at 37 °C was similar for variants and
wild type (day 7: 55–70 %).
Blood clearance studies were performed in BALB/c
nu/nu mice (n = 5) using 125I-labelled antibody co-
injected with their 111In-CHX-A″ DTPA-labelled coun-
terpart, and blood clearance parameters were calculated
(Table 2). There was no significant difference between
the elimination half-lives (t1/2β) of radioiodinated or
radiometal-chelated hu3S193 wild type. Radioiodinated
hu3S193 variants showed shorter half-lives than their
radiometal counterpart; the shorter the half-life the
smaller the differences in half-lives observed between
radioiodinated and radiometal-chelated hu3S193 mu-
tants. Although different terminal serum half-lives
were seen dependent on the choice of isotope, a simi-
lar ranking order of area under the curve (AUC) was
observed: wild type>H435A = I253A>H310A>I253A/
H310A (Table 2).
Biodistribution studies in tumour-bearing mice with 131I-
and 111In-CHX-A″ DTPA-labelled hu3S193 antibodies
In general, a significant reduction in tumour uptake was
observed with faster clearing variants; the faster the blood
clearance of the variant, the higher the reduction in
tumour uptake (Fig. 1). Additional file 1: Table S2 shows
the biodistribution results of 111In-CHX-A″ DTPA-
labelled antibodies. Additional file 1: Table S3 shows the
biodistribution results of 131I-labelled antibodies. Two-
way ANOVA of differences in tumour uptake at different
time points post injection of each variant compared to
Table 1 Immunoreactive fraction (% total binding) of hu3S193
antibodies incubated in human serum at 37 °C for 6 days
Radiolabel Antibody D0 D2 D6
125I- Wild type 78.64 ± 1.59a 59.09 ± 5.54 32.36 ± 0.12
I253A 66.76 ± 0.33 47.50 ± 2.69 30.99 ± 0.77
H310A 70.75 ± 3.99 53.52 ± 3.53 32.95 ± 0.28
H435A 69.50 ± 0.33 54.59 ± 4.68 34.82 ± 2.98
I253A/H310A 71.93 ± 3.22 58.29 ± 0.33 30.52 ± 1.45
111In- Wild type 86.84 ± 0.74 64.46 ± 8.04 40.21 ± 0.62
I253A 83.47 ± 4.26 59.16 ± 3.05 40.77 ± 0.53
H310A 81.03 ± 3.38 55.83 ± 1.78 35.64 ± 0.29
H435A 83.38 ± 3.81 59.70 ± 7.27 46.19 ± 4.63
I253A/H310A 86.07 ± 2.74 57.18 ± 11.61 42.54 ± 1.15
aData are presented as average ± SD (D2 125I-, n = 2; D6 125I- and 111In-, n = 2;
rest n = 4)
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wild type is shown in Additional file 1 (111In-labelled vari-
ants versus 111In-labelled wild type, Additional file 1:
Figure S1; 131I-labelled variants versus 125I-labelled wild
type, Additional file 1: Figure S2). Radioiodinated hu3S193
antibodies cleared faster than their 111In-chelated
counterparts, and as a result, lower tumour uptake was
observed with radioiodinated variants compared to
their 111In-chelated counterparts (Fig. 1, Additional
file 1: Table S2 and Additional file 1: Table S3).
Although a significant reduction in tumour uptake
was observed with faster clearing hu3S193 mutants,
more favourable tumour-to-blood ratios were observed
for 111In-labelled hu3S193 H310A and 111In-labelled
hu3S193 I253A/H310A compared to wild type (Table 3).
At 48 h post injection, 111In-labelled wild type showed a
tumour-to-blood ratio of 2.70 ± 0.26 compared to 5.04 ±
2.04 for H310A (P < 0.05) and 32.81 ± 7.10 for I253A/
H310A (P < 0.001). Tumour uptake was significantly
lower for all 131I-labelled mutants compared to wild type
(P < 0.0001) at all time points except 4 h post injection
(Fig. 1, Table 3, Additional file 1: Table S3, Additional
file 1: Figure S2). No significant differences in tumour
uptake were observed between mutants. As seen with
the 111In-labelled mutants at 48 h post injection,
tumour-to-blood ratios for 131I-labelled mutants were
more favourable than wild type (Table 3).
As expected for large proteins (>60 kDa), all
hu3S193 variants exhibited a hepatic clearance. This
is evidenced by the 111In-labelled variants showing an
increase in liver uptake at early time points with in-
creased blood clearance rates (Fig. 1f ). Liver uptake
for the slowest clearing mutants hu3S193 H435A and
hu3S193 I253A peaked at 4 h p.i. (9.49 ± 0.76 %ID/g
and 15.52 ± 3.45 %ID/g, respectively). The fastest mu-
tant hu3S193 I253A/H310A reached a maximum liver
uptake at 24 h p.i. (18.68 ± 1.34 %ID/g).
Improved therapeutic ratio with Fc-engineered hu3S193
mutants
To calculate the therapeutic ratio for hu3S193 variants
with faster blood clearance, AUC values were calculated
for blood of labelled (131I-, 90Y-, 177Lu-) antibodies and
tumour-to-blood AUC ratios were calculated (Table 4).
With exception of the I253A variant, all mutants demon-
strated higher or similar tumour-to-blood AUC ratios
compared to hu3S193 wild type. The highest increase in
tumour-to-blood AUC ratio was observed with the metal-
labelled mutants with 177Lu-CHX-A″ DTPA-hu3S193
I253A/H310A showing a doubling in the tumour-to-blood
AUC ratio compared to hu3S193 wild type and other vari-
ants. No increase in tumour-to-blood AUC ratios was
observed with the faster clearing radioiodinated variants.
AUC ratios were also calculated for tumour-to-liver
and tumour-to-kidney as these clearing organs could be
dose limiting, especially for radiometal-labelled mu-
tants. The lowest tumour-to-liver AUC ratios were ob-
served with the 90Y-labelled (1) and 177Lu-labelled (1.9)
hu3S193 I253A/H310A. Tumour-to-kidney ratios were
lowest for 90Y-hu3S193 I253A (2.4) and 90Y-hu3S193
I253A/H310A (2.5) followed by 90Y-hu3S193 H310A
(3.1) and 177Lu-hu3S193 H310A (3.1). Tumour-to-liver
AUC ratios were superior for the 131I-labelled variants
with the highest tumour-to-liver AUC ratio observed
with 131I-hu3S193 I253A/H310A (5.6).
Dosimetry calculation for radioimmunotherapy
To predict which hu3S193 mutant would be the best
candidate for radioimmunotherapy, dose-limiting
toxicity for the bone marrow was set at 150 cGy
[21]. 90Y-CHX-A″ DTPA-hu3S193 H310A reached a
tumour-absorbed dose 1.2-fold higher than hu3S193
wild type (H310A, 4050 cGy; wild type, 3300 cGy)
(Fig. 2). 177Lu-CHX-A″ DTPA-hu3S193 I253A/H310A
Table 2 Blood clearance parameters for 125I- and 111In-CHX-A″ DTPA-labelled hu3S193 antibodies
Radiolabel Antibody t1/2α (h) Aα
a (%ID/g) t1/2β (h) Aβ (%ID/g) AUC
b (%ID/g h) MRTc (h)
125I- Wild type 2.5 36.5 140.7 35.3 7304 199.4
I253A 0.7 18.1 13.2 60.0 1161 18.7
H310A 0.6 17.7 7.6 74.0 824 10.7
H435A 1.2 28.8 15.6 56.2 1316 21.7
I253A/H310A 0.5 15.7 7.3 66.5 710 10.3
111In-CHX-A″ DTPA- Wild type 2.6 37.2 151.5 31.5 7033 214.4
I253A 2.7 34.1 63.2 44.6 4200 88.46
H310A 1.5 38.9 24.4 46.9 1732 33.6
H435A 1.9 39.6 62.2 38.6 3567 87.0
I253A/H310A 0.5 20.0 9.1 58.7 781 12.9
aAmplitudes of the two components t1/2α and t1/2β are given by Aα and Aβ, respectively, where the sum of Aα and Aβ is the total %ID/g
bAUC area under the curve; time integral of the blood uptake
cMRT mean residence time; used to give a single variable for blood clearance
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was predicted to be the best candidate for 177Lu-therapy,
reaching a tumour dose of 8947 cGy compared to
4650 cGy for 177Lu-labelled wild type, limited by bone
marrow toxicity (Fig. 2).
Nano-SPECT imaging with 177Lu-CHX-A″ DTPA-labelled
hu3S193 wild type and 177Lu-CHX-A″ DTPA-labelled
hu3S193 I253A/H310A
Qualitative imaging was performed with hu3S193 wild
type, hu3S193 I253A/H310A and huA33 control in
A431 tumour-bearing mice. Mice were injected with
3.7 MBq (100 μCi, 270 μg) of radiolabelled antibody.
HuA33 wild type was used as a negative control as the
A431 cell line does not express A33 antigen. Quality
controls showed that at day 0, only 3.4 % of 177Lu-CHX-A″
DTPA-labelled huA33 bound to A431 cells in vitro. In
contrast, 177Lu-CHX-A″ DTPA-labelled hu3S193 wild
type and I253A/H310A demonstrated a good binding at
day 0 (72.6 ± 4.3 % and 53.9 ± 3.9 %, respectively; n = 3, SD)
gradually decreasing to 25.0 ± 2.5 % (wild type) versus 18.4
± 1.4 % (I253A/H310A) after 6 days of incubation in
human serum at 37 °C.
Whole body scans were obtained at 48 h post injec-
tion (Fig. 3). By 48 h, images showed tumour uptake
for 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type
(Fig. 3a, d) and I253A/H310A (Fig. 3b, e). No tumour
Fig. 1 Biodistribution with 131I- (a, c and e) and 111In-CHX-A″ DTPA-labelled (b, d and f) hu3S193 antibodies. n = 5; bars, SD
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uptake was shown with the huA33 control demon-
strating specific tumour uptake of hu3S193 wild type
and I253A/H310A mutant in A431 tumours (Fig. 3c,
3f ). High tumour uptake, high blood pool and back-
ground activity for hu3S193 wild type compared to
hu3S193 I253A/H310A were observed. Volume of
interest analysis for the heart, liver and tumour was
used to calculate averaged uptake per pixel. Hu3S193
wild type had a lower tumour-to-heart ratio compared
to I253A/H310A (wild type, 2.53 ± 0.07; I253A/H310
A, 7.34 ± 2.05; n = 2). The tumour-to-liver ratio was
higher for wild type (4.40 ± 1.51, n = 2) compared to
I253A/H310A (1.35 ± 0.15; n = 2).
In a separate biodistribution study, mice were
injected with 177Lu-CHX-A″ DTPA-labelled hu3S193
wild type or I253A/H310A (n = 5). After 48 h post in-
jection, mice were sacrificed and organs were counted
for radioactivity (Table 5). Biodistribution results con-
firmed reduced tumour activity of I253A/H310A
(16.95 ± 3.60 %ID/g) compared to hu3S193 wild type
(44.81 ± 3.35 %ID/g; P < 0.01). Tumour uptake of 177Lu-
CHX-A″ DTPA-labelled I253A/H310A was specific and
significantly higher than 177Lu-CHX-A″ DTPA-labelled
huA33 (10.35 ± 0.54, P < 0.01). Importantly, tumour-to-
blood ratios were 2.93 ± 0.65 (hu3S193 wild type), 0.49 ±
0.30 (huA33 control) and 16.56 ± 3.71 (hu3S193 I253A/
Table 3 Tumour uptake, blood levels and tumour-to-blood ratios for 131I- and 111In-CHX-A″ DTPA-labelled hu3S193 antibody variants
in A431 tumour-bearing mice
Antibody Time (hours) Tumour (%ID/g) Blood (%ID/g) T/B Tumour (%ID/g) Blood (%ID/g) T/B
131I 111In
Wild type 4 9.02 ± 0.73a 39.37 ± 3.33 1:4 13.17 ± 2.40 35.56 ± 5.48 1:3
24 17.37 ± 1.25 22.17 ± 1.81 1:1 33.42 ± 7.75 21.83 ± 3.32 2:1
48 17.58 ± 2.60 15.09 ± 1.70 1:1 39.01 ± 3.92 14.50 ± 1.11 3:1
72 17.76 ± 1.72 13.18 ± 1.91 1:1 39.27 ± 4.33 9.97 ± 1.85 4:1
120 15.10 ± 3.89 7.13 ± 1.46 2:1 37.26 ± 8.67 5.78 ± 2.12 6:1
168 11.40 ± 4.56 4.44 ± 1.56 2:1 24.24 ± 2.57 1.06 ± 0.32 9:1
I253A 4 10.01 ± 3.25 29.95 ± 3.59 1:3 9.64 ± 0.74 38.74 ± 3.57 1:4
24 9.95 ± 2.26 6.94 ± 1.34 1:1 27.17 ± 2.00 17.99 ± 1.57 2:1
48 5.07 ± 2.10 1.09 ± 0.32 5:1 31.75 ± 3.98 10.19 ± 1.04 3:1
72 2.03 ± 0.81 0.04 ± 0.08 48:1 33.11 ± 4.05 7.64 ± 1.32 4:1
120 0.78 ± 0.79 0.00 ± 0.00 >500:1 23.68 ± 6.52 2.99 ± 0.73 8:1
168 0.10 ± 0.14 0.00 ± 0.00 >500:1 14.66 ± 4.80 1.14 ± 0.63 13:1
H435A 4 8.79 ± 0.45 32.46 ± 2.63 1:4 10.25 ± 1.30 37.97 ± 2.68 1:4
24 11.52 ± 1.38 8.46 ± 1.89 1:1 33.69 ± 3.77 17.09 ± 1.59 2:1
48 5.53 ± 1.18 2.27 ± 1.21 2:1 31.10 ± 4.76 7.65 ± 1.60 4:1
72 3.18 ± 0.22 0.69 ± 0.17 5:1 28.48 ± 4.00 5.18 ± 1.40 6:1
120 1.64 ± 1.09 0.00 ± 0.00 >500:1 25.60 ± 4.16 3.19 ± 0.62 8:1
168 0.54 ± 0.58 0.00 ± 0.00 >500:1 15.34 ± 4.65 1.16 ± 0.62 13:1
H310A 4 9.80 ± 1.83 32.56 ± 3.00 1:3 10.79 ± 2.87 30.52 ± 5.06 1:3
24 9.58 ± 1.73 3.85 ± 0.35 3:1 22.85 ± 2.93 11.05 ± 1.62 2:1
48 5.10 ± 1.87 0.01 ± 0.02 >500:1 25.10 ± 2.91 5.61 ± 2.01 5:1
72 2.43 ± 1.10 0.00 ± 0.00 >500:1 22.12 ± 2.55 2.56 ± 0.60 9:1
120 1.81 ± 0.71 0.00 ± 0.00 >500:1 12.89 ± 1.33 0.54 ± 0.16 24:1
168 1.45 ± 0.99 0.00 ± 0.00 >500:1 8.64 ± 0.96 0.17 ± 0.06 51:1
I253A/H310A 4 9.90 ± 2.42 30.20 ± 3.97 1:3 8.92 ± 2.00 28.84 ± 6.05 1:3
24 8.04 ± 1.82 3.88 ± 1.32 2:1 23.72 ± 0.85 5.28 ± 0.81 5:1
48 5.10 ± 0.76 0.06 ± 0.09 80:1 14.84 ± 1.43 0.46 ± 0.07 32:1
72 3.04 ± 1.58 0.00 ± 0.00 >500:1 11.92 ± 2.46 0.08 ± 0.03 154:1
120 1.92 ± 0.53 0.00 ± 0.00 >500:1 5.85 ± 1.31 0.00 ± 0.00 >500:1
168 1.43 ± 0.27 0.00 ± 0.00 >500:1 3.52 ± 1.00 0.00 ± 0.00 >500:1
aData presented as percentage injected dose per gramme tissue (mean ± SD, n = 5)
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H310A). Tumour-to-liver ratios were 7.71 ± 1.26 (hu3S193
wild type), 6.37 ± 0.62 (huA33 control) and 1.20 ± 0.23
(hu3S193 I253A/H310A).
Higher protein doses were used for imaging with
177Lu-CHX-A″ DTPA-labelled hu3S193 antibodies
(270 μg) and biodistribution (100 μg). Tumour uptake
with 5 μg (~0.25 mg/kg) 111In-CHX-A″ DTPA-labelled
hu3S193 antibodies was not significantly different from
tumour uptake with 100 μg (~5 mg/kg) 177Lu-CHX-A″
DTPA-labelled hu3S193 antibodies as shown in
Additional file 1: Figure S3, suggesting that at least at
the 5 mg/kg dose level, no blocking of receptor has
occurred.
Discussion
Fc engineering is a promising technique to increase the
therapeutic ratio for payload delivery. This approach
aims to increase the therapeutic efficacy by reducing the
terminal half-life of antibodies or Fc-containing antibody
constructs, thus reducing the dose-limiting toxicity to
the blood and bone marrow of intact radiolabelled thera-
peutic antibodies. In this study, four variants of an intact
IgG1 antibody, hu3S193, with a broad range in half-life
were created by site-directed mutagenesis and analysed
in blood clearance studies and biodistribution studies.
Our results show that hu3S193 can be engineered with
improved therapeutic ratios for 90Y- and 177Lu-based
therapy, with the best candidate being hu3S193 I253A/
H310A for 177Lu-based therapy, achieving almost
double tumour-to-blood AUC ratios compared to wild-
type hu3S193.
Four Fc variants of an intact IgG1 antibody, hu3S193,
with a broad range in serum half-life were created by
site-directed mutagenesis and analysed in preclinical
blood clearance studies and biodistribution studies.
Non-specific uptake of hu3S193 wild type in a Lewis-Y-
negative cell line SW1222 is known to be low [26]; in
addition, in this study, a non-specific IgG1 control
Table 4 AUC values (%ID/g h) and therapeutic ratios of 131I-, 90Y-CHX-A″ DTPA- and 177Lu-CHX-A″ DTPA-labelled hu3S193 antibody
variants in A431 tumour-bearing mice
Radiolabel Antibody AUCtumour AUCblood AUCliver AUCkidney T/L
a T/Kb T/Bc
90Y-CHX-A" DTPA- Wild type 2849 1276 498 636 5.7 4.5 2.2
H435A 2168 964 514 561 4.2 3.9 2.3
I253A 1541 1126 738 633 2.1 2.4 1.4
H310A 1506 559 676 482 2.2 3.1 2.7
I253A/H310A 1037 418 1037 412 1.0 2.5 2.5
177Lu-CHX-A" DTPA- Wild type 5203 1709 833 1265 6.3 4.1 3.1
H435A 4076 1235 835 932 4.9 4.4 3.3
I253A 3514 1362 1189 1029 3.0 3.4 2.6
H310A 2400 783 1104 774 2.2 3.1 3.1
I253A/H310A 2699 453 1421 539 1.9 5.0 6.0
131I- Wild type 2739 2085 560 659 4.9 4.2 1.3
H435A 679 516 129 175 5.2 3.9 1.3
I253A 568 516 141 159 4.0 3.6 1.1
H310A 655 439 118 125 5.5 5.2 1.5




Fig. 2 Maximum tumour dose predictions of 131I-, 90Y- and 177Lu-
labelled hu3S193 wild type and variants. The limiting organ toxicity
is set at 150 cGy for the bone marrow
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antibody huA33 showed low uptake in A431 tumours
at 72 h post injection. Therefore, the tumour uptake
of radiolabelled hu3S193 mutants was specific and
antigen-mediated.
Early engineering approaches using deletion of
constant domains to reduce the serum half-life of anti-
bodies have shown that tumour-to-normal dose ratios
can be improved [1, 10, 11, 37]. More recently, studies
by Kenanova et al. reported on therapy prospects of
radioiodinated and radiometal-labelled Fc-engineered
anti-carcinoembryonic antigen (CEA) scFv-Fc frag-
ments [20, 21]. Dosimetry calculations predicted that
the 131I-labelled scFv-Fc H310A/H435Q could deliver
>7000 cGy, limited by red marrow toxicity. 90Y-labelled
Fig. 3 Nano-SPECT/MRI imaging with 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type (a, d) and I253A/H310A mutant (b, e) and huA33 wild type antibody
(c, f) at day 2 post injection in A431 tumour-bearing mice. Representative whole body surface-rendered MRI images (a–c) and maximum intensity
projection SPECT image (d–f) are shown for each antibody. The T1 weighted MRI images clearly show the tumour (grey solid mass) surface of
the lower abdomen, corresponding to the specific uptake of 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type and I253A/H310A in tumours
expressing Ley. Specific uptake of both hu3S193 wild type and hu3S193 I253A/H310A was demonstrated by the absence of huA33 uptake in
the A33 antigen-negative A431 tumours
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scFv-Fc I253A was best suited for 90Y delivery, al-
though dose predictions did not match the intact
cT84.66 antibody. The current study extends their
findings to an intact IgG1 and includes predictions
for 177Lu-based therapy. In contrast to the anti-CEA
study by Kenanova et al., the radioiodinated anti-Ley
hu3S193 variants cleared much faster than the radio-
iodinated scFv-Fc fragments, and therefore, no
therapeutic benefit could be obtained from the radio-
iodinated hu3S193 variants. The hu3S193 variants
might be more sensitive to deiodination in vivo com-
pared to the scFv-Fc variants. To study the benefit for
RIT of using radioiodinated hu3S193 variants with faster
blood clearance, other radioiodination methods such as
site-specific radioiodination of cysteine-containing hu3S193
variants could be explored [38].
Whilst a doubling in dose to the maximum predicted
dose calculated for hu3S193 wild type was predicted and
a doubling in the tumour-to-blood AUC ratios achieved,
the dose needed for tumour eradication in patients is
likely to be higher than that achievable with a single in-
fusion. Ley-expressing tumours such as colon, lung,
ovarian and breast cancer require radiation doses of at
least 60 Gy to eradicate solid tumours in patients [1].
Reducing the half-life of systemically administered
antibodies is usually associated with reduced uptake in
tumour; however, AUC ratios of tumour and blood ad-
dress the varying effects of alterations in antibody
kinetics, and our results confirm that selective IgG1
mutations do provide benefit in therapeutic ratios. Ap-
proaches to further increase therapeutic efficacy of Fc-
engineered intact antibodies with reduced half-lives can
include dose fractionation [39], use in pretargeting
radioimmunotherapy approaches [40] or combination
with chemotherapy [28, 29]. To date, pretargeting ap-
proaches show advantages compared to improvements
in one-step RIT for improved tumour-to-normal tissue
AUC ratios and tumour responses in preclinical models
of solid tumours [1], but challenges remain to develop
non-immunogenic and translatable approaches for hu-
man trials.
Due to the toxicity limitations of RIT and patient
tumour variability, it is useful to develop theranostics
to guide dosimetry in patients, exemplified in this study
by 177Lu-labelled I253A/H310A. The imaging results
reflect the biodistribution data; the highest tumour
uptake was seen with hu3S193 wild type, but specific
tumour uptake was still achievable with the fastest
clearing hu3S193 variant I253A/H310A, and tumour-to-
blood ratios were far higher at earlier time points with the
mutant hu3S193 constructs. However, because 177Lu can
only be imaged using SPECT cameras, a PET equivalent
such as 89Zr-labelled I253A/H310A might be a better
alternative and may allow better quantification of tumour
uptake and saturability in vivo. We are currently evaluat-
ing 89Zr-labelled hu3S193 variants in tumour-bearing
mice in small animal PET studies.
A higher protein dose was used for 177Lu-imaging
(270 μg) and biodistribution (100 μg) studies versus
111In-biodistribution (5 μg) studies. We demonstrated that
tumour uptake at 5 and 100 μg protein doses were com-
parable. Lewis-Y expression is very high on A431 cells and
similar to MCF-7 cells, estimated to express around
106–107 antibody binding sites [26]. A recent report on
ABT-806, a humanised antibody that specifically targets
epidermal growth factor receptor (EGFR), reports on cold
competition blocking of the 806 antibody in A431 tu-
mours [41]. EGFR is highly expressed in A431 cells, and
therefore, more than 20 mg/kg of cold ABT-806 anti-
body was needed to allow competition in vivo. It is
therefore expected that competition with hu3S193 anti-
bodies will only occur at doses higher than 20 mg/kg,
which aligns with the observation that at the 5 mg/kg
dose (100 μg), no reduction in tumour uptake was
observed at 48 h post injection.
Although significant increases in therapeutic doses
were predicted with some variants compared to hu3S193
wild type, increased toxicities to normal tissue such as
the liver and kidneys were also predicted. A shift in tox-
icity from the bone marrow to liver as toxicity limiting
organ for radiometal-labelled antibody variants with a
faster blood clearance is not surprising. As the antibody
variants clear faster from the body, radioactivity expos-
ure to the blood is reduced. In addition, due to the re-
duced binding affinity of the variants for FcRn, an
increase in catabolism is expected as the variants are no
longer recycled in the blood circulation and degraded in
the lysosomes (e.g. hu3S193 I253A/H310A) [19]. In
contrast to radioiodine, the small radiometal-labelled
metabolites are trapped in the lysosomes of hepatocytes
[42], and thus, a higher initial uptake of radioactivity
observed in the liver is the result of enhanced accumula-
tion of radiometal chelates after degradation of the
Table 5 Biodistribution at 48 h post injection of 177Lu-CHX-A″
DTPA-labelled hu3S193 wild type and I253A/H310A in tumour-
bearing mice
Tissue Hu3S193 wild type Hu3S193 I253A/H310A HuA33
Tumour 44.81 ± 3.35 16.95 ± 3.60 10.35 ± 0.54
Blood 15.67 ± 2.47 1.05 ± 0.27 20.88 ± 1.25
Liver 5.99 ± 1.43 14.16 ± 1.28 6.37 ± 0.62
Spleen 9.32 ± 1.33 13.77 ± 2.57 9.60 ± 0.88
Kidney 8.27 ± 4.36 3.91 ± 0.41 7.98 ± 0.51
Lung 9.79 ± 1.55 1.95 ± 0.25 12.06 ± 0.99
Heart 5.72 ± 1.09 2.66 ± 0.16 6.03 ± 0.49
Muscle 2.01 ± 0.44 1.03 ± 0.08 2.34 ± 0.44
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variants in the lysosomes of hepatocytes. However, a
mouse model might not be readily translatable to human
studies to estimate liver and kidney toxicities developing
from catabolites due to differences in stability of radiola-
belled conjugates in human serum and relative size of
tissue compartments between mouse and human. A
theranostic might therefore also aid in appropriate dose
selection when using engineered intact antibodies with
altered pharmacokinetics.
Conclusions
Four Fc variants of an intact IgG1 antibody, hu3S193,
with a broad range in serum half-life were created by
site-directed mutagenesis and analysed in preclinical
blood clearance studies and biodistribution studies. We
have shown that hu3S193 can be engineered with
improved therapeutic ratios for 90Y- and 177Lu-based
therapy, with the best candidate being hu3S193 I253A/
H310A for 177Lu-based therapy. These results are highly
relevant to utilising Fc engineering as a tool to improve
the clinical application of hu3S193 and other intact anti-
bodies especially for payload delivery.
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